Clinical Trials Browser

Phase 2 × Immunoglobulin Light-chain Amyloidosis × siltuximab × Clear all

NCT03315026 2025-11-04

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Phase 2 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma